Peter Llewellyn-Davies Insider Profile
4 Followers
Peter Llewellyn-Davies, Director at Shield Therapeutics, holds 186.67K shares in Shield Therapeutics (Ticker: GB:STX), holds ― shares in 2invest AG (Ticker: GB:0QBE), holds ― shares in Medigene (Ticker: DE:MDG1). Most recently, Peter Llewellyn-Davies Bought ― shares of Shield Therapeutics on Dec 13, 2022 for an estimated value of 10.00K .
Peter Llewellyn-Davies's Trading History
You May Also Like
Peter Llewellyn-Davies insider profile FAQ
What is the percentage of profitable transactions made by Peter Llewellyn-Davies?
The percentage of profitable transactions made by Peter Llewellyn-Davies is 0%.
What is the average return per transaction made by Peter Llewellyn-Davies?
The average return per transaction made by Peter Llewellyn-Davies is -29.70%.
What stocks does Peter Llewellyn-Davies hold?
Peter Llewellyn-Davies holds: GB:STX, DE:MDG1, GB:0QBE stocks.
What was Peter Llewellyn-Davies’s latest transaction?
Peter Llewellyn-Davies’s latest transaction was an Informative Buy of 10.00K .
What was Peter Llewellyn-Davies's most profitable transaction?
Peter Llewellyn-Davies’s most profitable transaction was an Informative Buy of GB:0QBE stock on November 15, 2019. The return on the trade was 0.00%.
What is Peter Llewellyn-Davies's role in Shield Therapeutics?
Peter Llewellyn-Davies's role in Shield Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
